Federal Register #2026-13164

DEA Import Registration Applications for Controlled Substances by Veterans Pharmaceuticals and United States Pharmacopeial Convention

This opportunity concerns applications to the Drug Enforcement Administration (DEA) for registration as importers of controlled substances for research and analytical purposes. - Government Buyer: - Department of Justice, Drug Enforcement Administration (DEA) - OEMs/Vendors: - Veterans Pharmaceuticals, Inc. - United States Pharmacopeial Convention - Products/Controlled Substances Requested: - Veterans Pharmaceuticals, Inc.: - Lysergic acid diethylamide (LSD) (part number 7315) - Marihuana Extract (part number 7350) - Marihuana (part number 7360) - Tetrahydrocannabinols (part number 7370) - Mescaline (part number 7381) - 3,4-Methylenedioxyamphetamine (part number 7400) - 5-Methoxy-N, N-dimethyltryptamine (part number 7431) - Dimethyltryptamine (part number 7435) - Psilocybin (part number 7437) - Psilocyn (part number 7438) - Methamphetamine (part number 1105) - United States Pharmacopeial Convention: - Marihuana Extract (part number 7350) - Marihuana (part number 7360) - Purpose and Notable Requirements: - Veterans Pharmaceuticals, Inc. intends to import these substances for research and clinical trials. - United States Pharmacopeial Convention will import Marihuana and Marihuana Extract for distribution as analytical reference standards for analytical testing of raw materials. - Both registrations explicitly exclude the import of finished dosage forms for commercial sale. - Only the specified activities (research, clinical trials, analytical reference standards) are authorized under these registrations.

Description

The United States Pharmacopeial Convention has applied to be registered as an importer of basic classes of controlled substances, specifically Marihuana Extract and Marihuana. The company plans to import these substances for distribution as analytical reference standards to its customers for analytical testing of raw materials. No other activities for these drug codes are authorized for this registration. Comments and hearing requests on the application can be submitted until July 30, 2026.

View original listing